Clinical Trial Update: Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma [NA]

View source ↗

Summary

This update reports the completion of a clinical trial investigating CD19 CAR T-cell immunotherapy for relapsed or refractory CD19+ leukemia and lymphoma. No ef…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• CD19 CAR-T cell therapy (CAR-T cell therapy targeting CD19)

Snippet

Sponsor: UWELL Biopharma | Conditions: Lymphoma Leukemia | NA | Status: COMPLETED